Literature DB >> 17011235

Strategies for developing vaccines against H5N1 influenza A viruses.

Taisuke Horimoto1, Yoshihiro Kawaoka.   

Abstract

Recent outbreaks of highly pathogenic avian influenza A virus (H5N1 subtype) infections in poultry and humans (through direct contact with infected birds) have raised concerns that a new influenza pandemic might occur in the near future. Effective vaccines against H5N1 virus are, therefore, urgently needed. Reverse-genetics-based inactivated vaccines have been prepared according to World Health Organization (WHO) recommendations and are now undergoing clinical evaluation in several countries. Here, we review the current strategies for the development of H5N1 influenza vaccines, and future directions for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011235     DOI: 10.1016/j.molmed.2006.09.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  29 in total

1.  Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B.

Authors:  Han Lei; Zhina Sheng; Qian Ding; Jian Chen; Xiaohui Wei; Dominic Man-Kit Lam; Yuhong Xu
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

Review 2.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

3.  New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

Authors:  M A Hoelscher; L Jayashankar; S Garg; V Veguilla; X Lu; N Singh; J M Katz; S K Mittal; S Sambhara
Journal:  Clin Pharmacol Ther       Date:  2007-10-24       Impact factor: 6.875

4.  Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.

Authors:  Weifeng Zhang; Lianyan Wang; Yuan Liu; Xiaoming Chen; Jiahui Li; Tingyuan Yang; Wenqi An; Xiaowei Ma; Ruowen Pan; Guanghui Ma
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

5.  Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.

Authors:  Shin Murakami; Ayaka Iwasa; Kiyoko Iwatsuki-Horimoto; Mutsumi Ito; Maki Kiso; Hiroshi Kida; Ayato Takada; Chairul A Nidom; Le Quynh Mai; Shinya Yamada; Hirotaka Imai; Yuko Sakai-Tagawa; Yoshihiro Kawaoka; Taisuke Horimoto
Journal:  Vaccine       Date:  2008-09-17       Impact factor: 3.641

6.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

7.  Avian influenza H5 hemagglutinin binds with high avidity to sialic acid on different O-linked core structures on mucin-type fusion proteins.

Authors:  Stefan Gaunitz; Jining Liu; Anki Nilsson; Niclas Karlsson; Jan Holgersson
Journal:  Glycoconj J       Date:  2014-02       Impact factor: 2.916

8.  The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells.

Authors:  Kester Haye; Svetlana Burmakina; Thomas Moran; Adolfo García-Sastre; Ana Fernandez-Sesma
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

9.  Two novel HLA-A*0201 T-cell epitopes in avian H5N1 viral nucleoprotein induced specific immune responses in HHD mice.

Authors:  Ying-Kit Cheung; Samuel Chak-Sum Cheng; Yan Ke; Yong Xie
Journal:  Vet Res       Date:  2009-11-27       Impact factor: 3.683

10.  Improved and simplified recombineering approach for influenza virus reverse genetics.

Authors:  Qinfang Liu; Shuai Wang; Guangpeng Ma; Juan Pu; Nicole E Forbes; Earl G Brown; Jin-Hua Liu
Journal:  J Mol Genet Med       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.